Gossamer Bio Announces Executive Management Transition and Promotion of Laura Carter, Ph.D., to Chief Scientific Officer
Gossamer Bio, Inc. (GOSS)
Last gossamer bio, inc. earnings: 3/24 07:00 am
Check Earnings Report
Company Research
Source: Business Wire
SAN DIEGO--(BUSINESS WIRE)--Gossamer Bio, Inc. (Nasdaq: GOSS), a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing and commercializing therapeutics in the disease areas of immunology, inflammation and oncology, today announced that Luisa Salter-Cid, Ph.D., Gossamer’s Chief Scientific Officer, is resigning from Gossamer effective April 30, 2021. On that date, Laura Carter, Ph.D., currently Gossamer’s Senior Vice President, Research & Translational Biology, will be promoted to Chief Scientific Officer.“I would like to thank Luisa for her many contributions to Gossamer Bio,” said Faheem Hasnain, Chairman, President and CEO of Gossamer Bio. “Luisa has assembled a world-class research team that has made significant progress in developing our pre-clinical pipeline, and we wish her the best of luck as she moves on to new endeavors.”Dr. Salter-Cid has served as Chief Scientific Officer since joining Gossamer in September 2018 following a distinguished
Show less
Read more
Impact Snapshot
Event Time:
GOSS
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
---|---|---|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
Last Price | ||
VWAP | ||
High:
|
Max Up |
High:
|
Low:
|
Max Down |
Low:
|
%
|
Post news range |
%
|
|
Price change |
|
|
Price Change Percentage |
|
|
S&P 500 (SPX) |
|
%
|
Volume ratio |
%
|
Volume | ||
Ticks | ||
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
GOSS alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
GOSS alerts
High impacting Gossamer Bio, Inc. news events
Weekly update
A roundup of the hottest topics
GOSS
News
- Gossamer Bio, Inc. (NASDAQ: GOSS) had its "overweight" rating re-affirmed by analysts at Piper Sandler. They now have a $15.00 price target on the stock.MarketBeat
- Gossamer Bio Announces Appointment of Steven D. Nathan, M.D., and Skye Drynan to its Board of Directors [Yahoo! Finance]Yahoo! Finance
- Gossamer Bio Announces Appointment of Steven D. Nathan, M.D., and Skye Drynan to its Board of DirectorsBusiness Wire
- Should You Buy Gossamer Bio (GOSS) After Golden Cross? [Yahoo! Finance]Yahoo! Finance
- Gossamer Bio, Inc. (NASDAQ: GOSS) had its "outperform" rating re-affirmed by analysts at Wedbush. They now have a $6.00 price target on the stock.MarketBeat
GOSS
Earnings
- 11/9/23 - Miss
GOSS
Sec Filings
- 3/28/24 - Form 4
- 3/28/24 - Form 4
- 3/28/24 - Form 4
- GOSS's page on the SEC website